In HCC models, the in vivo effectiveness of cathepsin G inhibition was less pronounced than in vitro, suggesting that compensatory pathways or the tumor microenvironment may limit the clinical impact of cathepsin G-targeted approaches [61]. The gene discussed is CTSG; the disease is hepatocellular carcinoma.